Biomea Fusion, Inc.
A clinical-stage biopharma developing oral drugs for diabetes and obesity.
BMEA | US
Overview
Corporate Details
- ISIN(s):
- US09077A1060
- LEI:
- Country:
- United States of America
- Address:
- 1599 INDUSTRIAL ROAD, 94070 SAN CARLOS
- Website:
- https://www.biomeafusion.com/
- Sector:
- Manufacturing
Description
Biomea Fusion is a clinical-stage biopharmaceutical company focused on the discovery and development of oral covalent small molecule drugs for the treatment of diabetes and obesity. The company's pipeline is centered on advancing novel therapies designed to address metabolic diseases. Key investigational products include icovamenib, a menin inhibitor being evaluated in the COVALENT-111 Phase II study for type 2 diabetes, and BMF-650, a next-generation oral GLP-1 receptor agonist in Phase I clinical trials for obesity. Biomea Fusion aims to develop treatments that can potentially offer durable benefits, including combination strategies with existing therapies.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| No filings match the current criteria. | |||||
Automate Your Workflow. Get a real-time feed of all Biomea Fusion, Inc. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Biomea Fusion, Inc.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Biomea Fusion, Inc. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
